Virtual Posters

Big Data

PO-001  ARNTL2 is a hypoxia-responsive master regulator of PDAC malignancy. Alvaro Curiel-Garcia¹, Carlo H. Maurer², Pasquale Laise³, Irina Sagalovskiy⁴, John A. Chabot⁴, Gulam A. Manji⁴, Alina Iuga⁵, Kristen Johnson⁶, Andrea Califano⁴, Kenneth P. Olive⁴. ¹Columbia University, New York, NY, ²Technische Universität München, Munich, Germany, ³Darwin Therapeutics, New York, NY, ⁴Columbia University, New York, NY, ⁵University of North Carolina, Chapel Hill, NC, ⁶University of New Hampshire, Manchester, NH.

PO-002  Initial retrospective analysis of mechanisms of FOLFIRINOX resistance using clinical and molecular data from the Know Your Tumor (KYT) pancreatic ductal adenocarcinoma (PDAC) cohort. James M. Davison¹, Greg Mayhew¹, Kirk Beebe¹, Joel R. Eisner¹, Dennis Ladnier², Eric A. Collisson³, Lynn M. Matrisian². ¹GeneCentric Therapeutics, Inc, Durham, NC, ²Pancreatic Cancer Action Network, Manhattan Beach, CA, ³Division of Hematology and Oncology, Department of Medicine and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA.

PO-003  Predictors for 30-day readmission in patients with pancreatic cancer who had DNR code status. Jasmeet Kaur¹, Tanveer Mir², Paramveer Singh³, Judie Goodman¹. ¹Saint Joseph Mercy Oakland Hospital, PONTIAC, MI, ²Wayne State University, Detroit, MI, ³Karmanos Cancer Center, Detroit, MI.

PO-004  Basal-like, Classical A, and Classical B subtypes of pancreatic cancer show distinct immuno-suppressive molecular profiles. Emily L. LaPlante¹, Dongliang Liu¹, Aleksandar Milosavljevic¹, Qizhi Yao¹. ¹Baylor College of Medicine, Houston, TX.

PO-005  Proteome profiling of Pancreatic Ductal Adenocarcinoma (PDAC) primary tumors in Caucasian, African Americans and Latinx patients. Henry C. H. Law¹, Andrea N. Riner², Jose G. Trevino³, Nicholas T. Woods¹. ¹University of Nebraska Medical Center, Omaha, NE, ²University of Florida, Gainesville, FL, ³Virginia Commonwealth University, Richmond, VA.

Diagnostics, Early Detection, and Imaging

PO-006  CircRTN4 promotes pancreatic cancer progression through a novel circRNA-miRNA-lncRNA pathway and stabilizing epithelial-mesenchymal transition protein. Chi Hin Wong¹, Ut Kei Lou¹, Frederic Khe-Cheong Fung¹, Joanna H. M. Tong², Ka-Fai To², Stephen Lam Chan³, Yangchao Chen⁴. ¹School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China-Hong Kong, ²Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China-Hong Kong, ³Department of Clinical Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China-Hong Kong, ⁴School of Biomedical Sciences, Faculty of Medicine, and Shenzhen Research Institute, The Chinese University of Hong Kong, Hong Kong, China-Hong Kong.
PO-007  Plasma-based detection of pancreatic cancer: A multiomics approach. Teng-Kuei Hsu¹, Tzu-Yu Liu¹, Billie Gould¹, Christine Decapite², Amer Zureikat², Alessandro Paniccia³, Eric Ariazi¹, Marvin Bertin¹, Richard Bourgon¹, Kaitlyn Coil¹, Hayley Donnella¹, Adam Drake¹, Julie M. Granka¹, Preet Kaur¹, Maggie C. Louie¹, Shivani Mahajan¹, Amit Pasupathy¹, Ofer Shapira¹, Peter Ulz¹, Chun Yang¹, C. Jimmy Lin¹, Randall Brand². ¹Freenome Holdings Inc., South San Francisco, CA, ²Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, ³Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA.

PO-008  Diagnostic accuracy of blood-based multi-omic biomarkers for pancreatic adenocarcinoma: A systematic review and meta-analysis. Laura E. Kane¹, Gregory S. Mellotte², Eimear Mylod¹, Rebecca O'Brien¹, Fiona O'Connell¹, Khanh Nguyen³, Croí E. Buckley¹, Jennifer Arlow³, David Mockler¹, Aidan D. Meade³, Barbara M. Ryan², Stephen G. Maher¹. ¹Trinity College Dublin, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Ireland, ³Technological University Dublin, Dublin, Ireland.

PO-009  Multi-omic profiling of patient pancreatic cyst fluid for the identification of a novel biomarker panel of patient cancer risk. Laura E. Kane¹, Gregory S. Mellotte², Simone Marcone¹, Barbara M. Ryan², Stephen G. Maher¹. ¹Trinity College Dublin, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Ireland.

PO-010  Detection of early tissue changes on historical CT scans in the regions of the pancreas gland that subsequently develop adenocarcinoma using quantitative textural analysis and fat fraction analysis. Ronald L. Korn¹, Daniel D. Von Hoff², Andre Burkett¹, Dominic Zygarlo¹, Taylor Brodie³, Kathleen Panak¹, Sweta Rajan¹, Derek Cridebring², Michael J. Demeure³. ¹Imaging Endpoints, Scottsdale, AZ, ²Translational Genomics Research Institute, Phoenix, AZ, ³Hoag Hospital, Newport Beach, CA.

PO-011  The spectrum of pathogenic germline variants in pancreatic cancer patients with multiple primary tumors. Valentyna Kryklyva¹, Lodewijk A.A. Brosens², Marjolijn J.L. Ligtengberg¹, Iris D. Nagtegaal¹. ¹Radboud university medical center, Nijmegen, Netherlands, ²University Medical Center Utrecht, Utrecht, Netherlands.

PO-012  The concept of artificial intelligence against pancreatic cancer. Subash Kumar¹. ¹DMI Lochbridge, Elkridge, MD.

PO-013  Comparison of novel healthcare delivery models on the uptake of genetic education and testing in families with a history of pancreatic cancer: The GENetic Education, Risk Assessment and TESting (GENERATE) Study. Nicolette J. Rodriguez¹, Constance S. Furniss², Matthew B. Yurgelun³, Chinedu Ukaegbu⁴, Pamela E. Constantinoiu⁵, Alison N. Schwartz⁶, Jill Stopfer⁶, Meghan Underhill-Blazey⁶, Barbara Kenner⁷, Scott Nelson⁸, Sydney Okumura⁹, Sherman Law⁹, Alicia Y. Zhou⁹, Tara B. Coffin¹⁰, Hajime Uno², Allyson Ocean¹¹, Florencia McAllister⁵, Andrew M. Lowy¹², Scott M. Lippman¹², Alison P. Klein¹³, Lisa Madlensky¹², Gloria M. Petersen¹⁴, Judy E. Garber¹, Michael G. Goggins¹³, Anirban Maitra⁵, Sapna Syngal³. ¹Dana-Farber Cancer Institute / Brigham and Women's Hospital / Harvard
PO-014  VISTA: VIual Semantic Tissue Analysis for pancreatic disease quantification in murine cohorts. Luke Ternes1, Ge Huang1, Christian Lanciall1, Guillaume Thibault1, Rachelle Riggers2, Joe Gray2, John Muschler1, Young Hwan Chang1. 1Oregon Health and Science University, Portland, OR, 2Oregon Health and Science University, Portland, OR.

Early Phase Clinical Trials

PO-015  A phase Ib/II trial of high dose ascorbic acid (AA) + paclitaxel protein bound (PP) + cisplatin (C) + gemcitabine (G) in patients (pts) with previously untreated metastatic pancreatic cancer (MPC). Gayle S. Jameson1, Erkut H. Borazanci1, Daniel D. Von Hoff2, Joshua D. Rabinowitz3, Michael S. Gordon1, Sarah D. LeGrand1, Courtney Snyder1, Karen Ansilodo1, Denise J. Roe4, Haiyong Han2. 1HonorHealth, Scottsdale, AZ, 2Translational Genomics Research Institute (TGen), Phoenix, AZ, 3Princeton University, Princeton, NJ, 4University of Arizona Cancer Center, Tucson, AZ.

Immunotherapy

PO-016  Directed evolution generates novel oncolytic H-1 paroviruses with improved therapeutic efficacy in virus-resistant pancreatic cancer cells. Pierre Garcin1, Monireh Kazemimanesh1, Hubert Lulka1, Nelson Duset2, Guillaume Labrousse1, Emilie Benuzzi1, Louis Buscail3, Pierre Cordelier1. 1Cancer Research Center of Toulouse, INSERM, Toulouse, France, 2Cancer Research Center of Marseilles, INSERM, Marseilles, France, 3Cancer Research Center of Toulouse, INSERM and Toulouse University Hospital, Toulouse, France.

PO-017  Application of oncolytic adenovirus to desmoplastic pancreatic cancer. Flora Hossain1, Fumihiro Higashino1. 1Hokkaido University, Sapporo, Japan.

PO-019 Reprogramming of naïve B cells in pancreatic cancer subverts humoral immunity. Bhalchandra Mirlekar¹, Yuliya Pylayeva-Gupta¹. ¹Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.

PO-020 Heating up immune cold pancreatic adenocarcinoma with bioengineered immunotherapy remodels tumor microenvironment and prevents metastasis in vivo. Chanthirika Ragulan¹, Patrick Varun Lawrence¹, Hari PS¹, Krisha Desai¹, Jun Ishihara², Anguraj Sadanandan¹. ¹The Institute of Cancer Research, Sutton, United Kingdom, ²Imperial College London, London, United Kingdom.

**Metabolism**

PO-021 Targeting the mitochondrial pyruvate complex to alter metabolic programming in pancreatic cancer. Hassan A. Ali¹, Andrew Metcalfe², James T. Topham², Cassia S. Warren², Joanna M. Karasinska², David F. Schaeffer², Daniel J. Renouf³. ¹University of British Columbia, Vancouver, BC, Canada, ²Pancreas Centre BC, Vancouver, BC, Canada.

PO-023 Impaired adipose anabolism drives fat wasting in pancreatic cancer cachexia. Katherine Pelz¹, Grace McCarthy¹, Heike Mendez¹, Samantha Z. Brown¹, Jonathan R. Brody¹, Aaron J. Grossberg¹. ¹Oregon Health & Science University, Portland, OR.

PO-024 Targeting cellular metabolism with CPI-613 sensitizes pancreatic cancer cells to radiotherapy. William A. Hall¹, Husain Y. Khan², Mandana Kamgar¹, Susan Tsai¹, Kathleen Christians¹, Douglas B. Evans¹, Philip Philip², Callisia Clarke¹, Ben George¹, Beth Erickson¹, Asfar S. Azmi². ¹Medical College of Wisconsin, Milwaukee, WI, ²Karmanos Cancer Institute, Wayne State University, Detroit, MI.


PO-026 CircMYOF acts as a miR-4739 sponge to promote progression and facilitate glycolysis via VEGFA/Pi3K/AKT pathway in pancreatic ductal adenocarcinoma. Dandan Zheng¹, Xianxian Huang², Juanfei Peng¹, Yanyan Zhuang¹, Yuanhua Li³, Junchi Qu¹, Shineng Zhang¹, Fengting Huang¹. ¹Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China, ²the Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, China, ³Tungwah Hospital of Sun Yat-sen University, Dongguan, China.


PO-028 Pancreatic ductal adenocarcinoma is dependent on an unconventional pathway for polyamine synthesis. Min-Sik Lee¹,²,³, Insia Naqvi¹, Courtney Dennis³, Lucas Dailey⁴, Alireza Lorzadeh⁵, Tamara Zaytouni¹, Ashley Adler¹,³, Daniel S. Hitchcock⁴, Lin Lin¹, Unmesh Jadhav⁵,⁶, Clary B. Clish⁴, and Nada Y. Kalaany¹,²,³. ¹Division of
Endocrinology, Boston Children’s Hospital, Boston, MA, 2Department of Pediatrics, Harvard Medical School, Boston, 3Broad Institute of MIT and Harvard, Cambridge, MA, 4Metabolomics Platform, Broad Institute of MIT and Harvard, Cambridge, MA, 5Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, 6Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA.

PO-029 Pancreatic cancer-associated cachexia as a 3-stage systemic disease with changes in body composition, tissue-specific wasting across time and alterations in glucose metabolism. Blanca Majem1, Insia Naqvi1, Courtney Dennis2, Lucas Dailey2, Clary B. Clish2, Nada Kalaany1. 1Boston Children's Hospital, Harvard Medical School, Boston, MA, 2Metabolomics Platform, Broad Institute of MIT and Harvard, Cambridge, MA.

PO-031 Lysosome inhibition overcomes resistance to CDK4/6 inhibition in PDA. Dilru Silva, Conan Kinsey, Martin McMahon. Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.

Microbiome

PO-033 Bacterial cytotoxin therapy limits tumor growth for pancreatic ductal adenocarcinoma. Amanda R. Decker1, Tetsuhiro Harimoto2, Steve A. Sastra1, Tal Danino2, Kenneth P. Olive1. 1Columbia University Medical Center, New York, NY, 2Columbia University, New York, NY.

Other

PO-034 CPSF3 inhibition halts pancreatic cancer cell proliferation by limiting core histone supplies. Abdulrahman A. Alahmari1, Carla Schwarz2, Emily Paterson2, Swati Venkat2, Arwen Tisdale2, Michael E. Feigin2. 1Roswell Park Comprehensive Cancer Center, Amherst, NY, 2Roswell Park Comprehensive Cancer Center, Buffalo, NY.

PO-036 LP184, a novel alkylating agent, is highly effective in pancreatic cancers with DNA damage repair defects. Diana Restifo1, Aditya Kulkarni2, Caleb Schimke2, Joseph McDermott2, Umesh Kathad2, Kishor Bhatia2, Panna Sharma2, Igor Astsaturov1. 1Fox Chase Cancer Center, Philadelphia, PA, 2Lantern Pharma, Dallas, TX.

PO-037 Development of an RGD CRISPR-modified Clostridium novyi NT Spores as an Intravenous Oncotherapy. Kaitlin M. Dailey1, Krysten Vance2, Kyle McAndrews3, Reed I. Jacobson4, Jandro Delgado4, Paige R. Johnson5, Taylor M. Woolery5, Megan Orr6, Jiha Kim7, Sanku Mallik5, Kenneth W. Bayles8, Michael A. Hollingsworth2, Amanda E. Brooks9. 1Eppley Institute for Cancer Research, University of Nebraska Medical Center, and Cell and Molecular Biology Program, Pharmaceutical Sciences Department, North Dakota State University, Omaha, NE, 2Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE, 3Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, Omaha,
NE, 4Department of Biological Sciences, North Dakota State University, Fargo, ND, 5Cell and Molecular Biology Program, Pharmaceutical Sciences Department, North Dakota State University, Fargo, ND, 6Department of Statistics, North Dakota State University, Fargo, ND, 7Cell and Molecular Biology Program, Pharmaceutical Sciences Department and Department of Biological Sciences, North Dakota State University, Fargo, ND, 8Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, 9Cell and Molecular Biology Program, Pharmaceutical Sciences Department, North Dakota State University, Fargo, ND and Department of Research and Scholarly Activity, Rocky Vista University, Ivins, UT, Fargo, ND.

PO-038  LAMC2: new player in stemness and tumor progression in pancreatic cancer. Donatella Delle Cave1, Tea Teresa Iavazzo1, Maria Mangini2, Gennaro Andolfi1, Teresa Pirozzi1, Annalisa Di Domenico1, Annachiara De Luca2, Enza Lonardo1. 1Institute of Genetics and Biophysics ‘Adriano Buzzati-Traverso’ (IGB), CNR, Naples, Italy, 2Institute of Biochemistry and Cellular Biology, National Research Council of Italy, Naples, Italy.

PO-039  Antiproliferative activity of inhibitors of RAD51, singly and in combination with chemotherapy drugs, against pancreatic cancer cell lines. Peter Ferguson1, Mark D. Vincent1, Yousef Najajreh2, Brian Shilton3, Stephen Ritter3, Rima Al-awar4, Richard Marcellus4, Mohammed Mohammed4, Methvin Isaac5, James Koropatnick4. 1London Health Sciences Centre, London, ON, Canada, 2Al Quds University, Jerusalem, Palestinian Territory, 3Western University, London, ON, Canada, 4Ontario Institute for Cancer Research, Toronto, ON, Canada.

PO-040  Nischarin is expressed in pancreatic ductal adenocarcinoma and is a potential target for drug repurposing. Jelena Grahovac1, Marijana Pavlovic1, Marija Ostojic1, Kristina Zivic1, Daniel Galun2, Tatjana Srdic-Rajic1. 1Institute for Oncology and Radiology of Serbia, Belgrade, Serbia, 2School of Medicine, University of Belgrade; First Surgical Clinic, Clinical Center of Serbia, Belgrade, Serbia.

PO-041  Systemic screening of gene delivery methods in pancreatic ductal adenocarcinoma cells. Dmytro Grygoryev1, Taelor Ekstrom1, Jason M. Link2, Rosalie C. Sears2, Jungsun Kim1. 1Cancer Early Detection Advanced Research Center, Knight Cancer Institute, Portland, OR, 2Oregon Health & Science University, Portland, OR.

PO-043  Cytidine deaminase protects pancreatic cancer cells from replicative stress and drive response to DNA-targeting drugs. Audrey Lumeau1, Nicolas Bery1, Cyril Ribeyre2, Samad Elkaoutari3, Guillaume Labrousse1, Miguel Madrid-Mencia1, Vera Pancaldi1, Marie-Jeanne Pillaire4, Valérie Bergoglio5, Nelson Dusseti3, Jean-Sébastien Hoffmann6, Louis Buscail7, Malik Lutzmann2, Pierre Cordelier1. 1Cancer Research Center of Toulouse, Toulouse, France, 2IGH Montpellier, Montpellier, France, 3Cancer Research Center of Marseille, Marseille, France, 4IPBS Toulouse, Toulouse, France, 5CBI Toulouse, Toulouse, France, 6IUCT Oncopole Toulouse, Toulouse, France, 7CHU Rangueil Toulouse, Toulouse, France.

PO-045  Targeting HNF1A-dependent cell proliferation and stemness in PDAC using BET inhibitors. Bharani Muppavarapu, Ethan Abel, Melanie Mayberry. Roswell Park Comprehensive Cancer Center, Buffalo, NY.

PO-046  The effect of neoadjuvant therapy on immune profiling of pancreatic ductal adenocarcinoma: a prospective study of the PREOPANC-1 randomized controlled trial. Diba Latifi, Willem de Koning, Sai ping Lau, Frederiek Grevers, Coen van Dam, Casper H. J. van Eijck, Dana A. M. Mustafa. Erasmus University Medical Center, Rotterdam, Netherlands.

PO-047  Optimizing the efficacy of 5-FU as a chemotherapeutic agent in advanced pancreatic ductal adenocarcinoma (PDAC) using MIAPaCa-2 and PANC-1 cells. Nkafu Bechem Ndemazie1, Andriana Inkoom1, Xue Y. Zhu1, Edward Agyare1. 1Florida A&M University, Tallahassee, FL.

PO-048  A novel chromatin remodeling domain of keratin 17 regulates transcription and promotes tumor aggression in pancreatic cancer. Chun-Hao Pan1, Robert Tseng1, Simon J. Hogg2, Gabriella Baraks1, Cindy V. Leiton1, Lucia Roa-Peña1, Natalia Marchenko1, Kenneth R. Shroyer1, Luisa F. Escobar-Hoyos3. 1Stony Brook University, Stony Brook, NY, 2Memorial Sloan Kettering Cancer Center, New York, NY, 3Yale University, New Haven, CT.

PO-049  Inhibiting MNK kinases promotes macrophage immunosuppressive phenotype to limit anti-tumor immunity. Thao ND Pham1, Christina Spaulding1, Mario A. Shields1, Mahmoud G. Khalafalla1, Daniel R. Principe2, David J. Bentrem1, Hidayatullah G. Munshi1. 1Feinberg School of Medicine, Northwestern University, Chicago, IL, 2Medical Scientist Training Program, College of Medicine, University of Illinois at Chicago, Chicago, IL.

PO-050  Precision Promise (PrP): An adaptive, multi-arm registration trial in metastatic pancreatic ductal adenocarcinoma (PDAC). Vincent J. Picozzi1, Anne-Marie Duliege2, Anirban Maitra3, Manuel Hidalgo4, Andrew Eugene Hendifar5, Gregory L. Beatty6, Sudheer Doss Doss2, Regina Deck2, Lynn M. Matrisian2, Julie Fleshman2, Diane M. Simeone7. 1Virginia Mason Hospital and Medical Center, Seattle, WA, 2Pancreatic Cancer Action Network, Manhattan Beach, CA, 3University of Texas MD Anderson Cancer Center, Houston, TX, 4Weill Cornell Medicine, New York, NY, 5Samuel Oschin Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 6University of Pennsylvania, Philadelphia, PA, 7NYU Langone Health, New York, NY.

PO-051  PANOVA-3: A phase III study of tumor treating fields with nab-paclitaxel and gemcitabine for front-line treatment of locally advanced pancreatic adenocarcinoma. Vincent J. Picozzi1, Teresa Macarulla2, Philip A. Philip3, Carlos R. Becerra4, Tomislav Dragovich5. 1Virginia Mason Hospital and Medical Center, Seattle, WA, 2Vall d'Hebrón University Hospital and Vall d'Hebrón Institute of Oncology, Barcelona, Spain, 3Karmanos
Cancer Institute, Detroit, MI, 4Baylor University Medical Center, Dallas, TX, 5Banner MD Anderson Cancer Center, Gilbert, AZ.

**PO-052** A pilot study of miRNA expression profile in surgically resected pancreatic ductal adenocarcinoma: Initial report from a bi-institutional cohort. Luca Pompella1*, Michela Falco2*, Carlo Caputo2*, Anna Grimaldi2, Giuseppe Tirino1, Severo Campione3, Francesca Sparano1, Maria Lucia Iacovino1, Chiara Carmen Miceli1, Carlo Molino4, Marco Montella5, Renato Franco5, Gennaro Galizia6, Giovanni Conzo7, Vincenzo Napolitano7, Annamaria Auricchio6, Francesca Cardella6, Fortunato Ciardiello1, Michele Caraglia2, Angela Lombardi2, Gabriella Misso2* and Ferdinando De Vita1*. 1Department of Precision Medicine, Division of Medical Oncology, University of Campania "L. Vanvitelli", Aversa, Italy, 2Department of Precision Medicine, Division of Molecular Pathology, University of Campania "Luigi Vanvitelli", Naples, Italy, 3Department of Precision Medicine, Division of Medical Oncology, University of Campania "L. Vanvitelli", Naples, Italy, 4Division of Surgical Pathology, AORN "Antonio Cardarelli", Naples, Italy, 5Division of General Surgery 1, AORN "Antonio Cardarelli", Naples, Italy, 6Division of Surgical Pathology, University of Campania "Luigi Vanvitelli", Naples, Italy, 7Department of Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy, 8Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy, 9Department of Precision Medicine, Division of Molecular Pathology, University of Campania "L. Vanvitelli", Naples, Italy. * These authors contributed equally to this work.

**PO-054** A phase II trial of the super-enhancer inhibitor Minnelide in advanced refractory adenosquamous carcinoma of the pancreas (ASCP). Nebojsa Skorupan1, Mehwish I. Ahmad1, Seth M. Steinberg1, Jane B. Trepel1, Derek Cridebring2, Haiyong Han2, Daniel D. Von Hoff2, Christine Alewine1. 1CCR, Bethesda, MD, 2Translational Genomics Research Institute, Phoenix, AZ.

**PO-055** Phase II clinical trial of subtype directed neoadjuvant therapy in patients with localized pancreatic cancer. Susan Tsai1, Erkut Borazanci2, Margaret Gulley3, Naim Rashid3, Jason Merker3, Abdul H Khan4, Phillip Chisholm1, Bryan Hunt1, Tamara Giorgadze1, William Hall1, Mandana Kamgar1, Douglas B Evans1, Jen Jen Yeh3. 1Medical College of Wisconsin, Milwaukee, WI, 2Honor Health Medical Group, Scottsdale, AZ, 3University of North Carolina, Chapel Hill, NC.

**PO-056** Insulin receptor signaling in pancreatic acinar cells contributes to pancreatic cancer development. Anni M.Y. Zhang, Jenny C.C. Yang, Twan J.J. de Winter, David F. Schaeffer, Janel L. Kopp, James D. Johnson. The University of British Columbia, Vancouver, BC, Canada.

**PO-057** Targeting ErbB2 degradation via the ubiquitin–proteasome pathway to inhibit
the metastasis of pancreatic cancer. Bo Zhang, Fei Teng, Nengming Lin. Hangzhou First People's Hospital, Hangzhou, China.

Preclinical Models

PO-058 Anti-cancer activity of NTAX-44 (bioprocessed arsenic trioxide) on pancreatic cancer cell line. Yogesh Bendale¹, Padma Shastr², Radha Poojari³, Nandine Khot², Surendra Nagare⁵, Avinash Kadam². ¹Rasayu Cancer Clinic, Pune, India, ²Rasayani Biologics Pvt. Ltd, Pune, India, ³Innovation Centre, Tata Chemicals Ltd., Pune, India.

PO-059 Epithelial/mesenchymal identity dictates pancreatic cancer cell metastasis. Julienne L. Carstens¹, Sujuan Yang¹, Pedro Correa de Sampaio¹, Xiaofeng Zheng¹, Souptik Barua², Kathleen M. McAndrews¹, Arvind Rao³, Jared K. Burks¹, Andrew D. Rhim¹, Raghu Kalluri¹. ¹MD Anderson Cancer Center, Houston, TX, ²Rice University, Houston, TX, ³University of Michigan, Ann Arbor, MI.

PO-060 N-terminal RHAMM cooperates with dysfunctional p53 to accelerate the progression of pancreatic cancer. Anthony Lin¹, Jennifer Feng¹, Xiang Chen¹, Dunrui Wang², Megan Wong¹, George Zhang¹, Joseph Na¹, Tiantian Zhang¹, Zhengming Chen¹, Yao-Tseng Chen¹, Yi-Chieh Nancy Du¹. ¹Weill Cornell Medicine, New York, NY, ²National Institutes of Health, Bethesda, MD.

PO-061 Myc drives phenotypic heterogeneity, metastasis, and therapy resistance in pancreatic ductal adenocarcinoma. Isabel A. English¹, Patrick J. Worth¹, Amy T. Farrell¹, Brittany L. Allen-Petersen², Vidhi Shah¹, Courtney Betts¹, Xiaoyan Wang¹, Colin J Daniel¹, Mary C. Thoma¹, Lisa M. Coussens¹, Ellen M. Langer¹, Rosalie C. Sears¹. ¹Oregon Health & Science University, Portland, OR, ²Purdue University, West Lafayette, IN.

PO-062 EUS-guided biopsy of pancreatic mass lesions for the development of patient-derived organoids in Puerto Rico. Andrea S. Flores Pérez¹, Janet Mendez Vega¹, Ana M. Reyes Ramos¹, Carlos Micames², Madeline Torres-Lugo¹, Maribella Domenech¹. ¹University of Puerto Rico - Mayagüez, Mayagüez, Puerto Rico, ²Hospital Bella Vista, Mayagüez, Puerto Rico.

PO-063 Functional interrogation of immune escape in neoantigen-expressing pancreatic cancer identifies a critical role for the CD155/TIGIT axis. William Freed-Pastor¹, Laurens Lambert¹, Zackery Ely¹, Nimisha Pattada¹, Arjun Bhutkar¹, Alex Jaeger¹, George Eng¹, Kim Mercer¹, William Hwang¹, Tyler Jacks¹. ¹MIT, Cambridge, MA.

PO-064 ONC212 stimulates cytotoxic T-cell killing, increases tumor-immune cell interactions, and promotes tumor regression in combination with TLY012 in a PDAC murine model. Kelsey E. Huntington¹, Anna Louie¹, Young Lee¹, Jared Mompoint¹, Isacco Ferrarini², Aakash Jhaveri³, Varun V. Prabhu⁴, Allen Melemed⁵, Seulki Lee⁵, Wafik S El-Deiry¹. ¹Brown University, Providence, RI, ²University of Verona, Verona, Italy, ³Sidney Kimmel Medical College, Philadelphia, PA, ⁴Chimerix, Durham, NC, ⁵D&D Pharmatech, Gaithersburg, MD.
PO-065  **SIWA318H, an advanced glycation end product (AGE) targeting antibody, is efficacious in a humanized mouse xenograft model for pancreatic cancer.** Ashley Jensen¹, Gabriela R. Rossi², Ruben Muñoz¹, Kimberly Brothers¹, Lewis Gruber², Misty Gruber², Haiyong Han¹. ¹Translational Genomics Research Institute, Phoenix, AZ, ²SIWA Therapeutics, Inc., Chicago, IL.

PO-066  **High uptake, retention, and in vivo activity of L-Annamycin in pancreatic cancer models.** Ya'an Kang, Rafal Zielinski, Roberto Cardenas Zuniga, Radjendirane Venugopal, Maria Pimenidou, Magdalena Remiszewski, Shaohua Peng, Edd Felix, Krzysztof Grela, Stanislaw Skora, Van N. Nguyen, Izabela Fokt, Waldemar Priebe. UT MD Anderson Cancer Center, Houston, TX.

PO-067  **A multi-omics study in patient-derived organoids reveals MNX1-HNF1B axis to be indispensable for intraductal mucinous papillary neoplasm lineages.** Hiroyuki Kato¹, Keisuke Tateishi¹, Keisuke Yamamoto¹, Dousuke Iwadate¹, Hiroaki Fujiwara², Takuma Nakatsuka¹, Koji Miyabayashi¹, Yotaro Kudo¹, Ijichi Hideaki¹, Kazuhiko Koike³, Mitsuhiko Fujishiro¹. ¹Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ²Division of Gastroenterology, The Institute for Adult Diseases, Asahi Life Foundation, Tokyo, Japan, ³Department of Gastroenterology, Kanto Central Hospital, Tokyo, Japan.

PO-068  **Cholesterol auxotrophy promotes the expansion of centroacinar cells giving rise to the basal subtype of pancreatic adenocarcinoma.** Michael Kotliar¹, Aizhan Surumbayeva², Linara Gabitova², Suraj Peri³, Diana Restifo³, Kathy Q. Cai³, Artem Barski⁵, Igor Astsaturov². ¹Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²The Marvin & Concetta Greenberg Pancreatic Cancer Institute, Fox Chase Cancer Center, Philadelphia, PA, ³Biostatistics and Bioinformatics Facility, Fox Chase Cancer Center, Philadelphia, PA, ⁴Histopathology Facility, Fox Chase Cancer Center, Philadelphia, PA, ⁵Cincinnati Children’s Hospital Medical Center and Department of Pediatrics, University of Cincinnati, Cincinnati, OH.

PO-069  **Modeling the tumor microenvironment using tissue engineering technologies.** Rodrigo Curvello¹, Verena Kast², Daniela Loessner¹. ¹Monash University, Clayton, Australia, ²Max Bergmann Center of Biomaterials Dresden, Dresden, Germany.

PO-070  **Longitudinal precision oncology platform to identify chemotherapy-induced vulnerabilities in pancreatic cancer.** Katja Peschke¹, Hannah Jakubowski¹, Arlett Schäfer¹, Carlo Maurer¹, Sebastian Lange¹, Felix Orben¹, Raquel Bernad¹, Felix Harder¹, Matthias Eiber¹, Rupert Öllinger¹, Melissa Schlitter¹, Wilko Weichert¹, Veit Phillip¹, Christoph Schlag¹, Roland Schmid¹, Rickmer Braren¹, Bo Kong², Ekin Demir², Helmut Friess¹, Roland Rad¹, Dieter Saur¹, Günter Schneider¹, Maximilian Reichert¹. ¹Technical University of Munich, Klinikum rechts der Isar, Munich, Germany, ²University of Ulm, Ulm, Germany.

PO-072  **Inhibiting vasoactive intestinal peptide receptor signaling elicits T cell dependent anti-tumor response of pancreatic ductal adenocarcinoma to immune checkpoint therapy.** Sruthi Ravindranathan¹, Passang Tenzin¹, Jian Ming Li¹, Rohan
Dhamsania1, Michael Ware1, Mohammad Zaidi1, Shuhua Wang1, Jingru Zhu1, Maria Cardenas1, Yuan Liu1, Gaurav Joshi1, Sanjeev Gumber1, Brian Robinson1, Anish Sen-Majumdar2, Shanmuganathan Chandrakasan1, Haydn Kissick1, Alan Frey2, Susan Thomas3, Bassel El-Rayes1, Gregory Lesinski1, Edmund K. Waller1. Emory University, Atlanta, GA. 2Cambium Oncology, Atlanta. 3Georgia Institute of Technology, Atlanta.

**PO-073**  
Inactivation of Notch4 attenuated pancreatic tumorigenesis in mice. Kiyoshi Saeki1, Wanglong Qiu1, Richard Friedman1, Carrie Shawber1, Jan Kitajewski2, Jianhua Hu1, Gloria H. Su1. 1Columbia University Irving Medical Center, New York, NY, 2University of Illinois Chicago, Chicago, IL.

**PO-074**  
Identification of C-MET receptor as a therapeutic target in patient-specific tumor models of metastatic pancreatic adenocarcinoma allows identification of a new mode of action for its inhibitors. Liam Deems, Maria Ivanova, Cheryl Murphy, Amit Shahar, David Deems, Dmitry Shvartsman. Cellaria Inc., Wakefield, MA.

**PO-075**  
The elucidation of the role of Prrx1 for acinar to ductal metaplasia in response to acute injury of pancreas in the novel mouse models. Kensuke Suzuki1, Alina Li1, Jason R. Pitarresi1, Anna M. Chiarella1, Gizem Efe1, Kensuke Sugiuara1, Rohit Chandwani2, Anil K. Rustgi1. 1Herbert Irving Comprehensive Cancer Center, Division of Digestive and Liver Diseases, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, 2Department of Surgery, Weill-Cornell Medical School, New York, NY.

**PO-076**  

**PO-077**  
Establishment of a novel living biobank of patient-derived pancreatic cancer organoids with genomic and drug response characterization. Irene Y. Xie1, Laura Tamblyn2, Karen Ng2, Eugenia Flores-Figueroa2, Julie M. Wilson3, Gun Ho Jang3, Amy X. Zhang3, Stephanie Ramotar2, Anna Dodd2, Nikolina Radulovich2, Jennifer J. Knox2, Grainne M. O’Kane2, Steven Gallinger2, Faiyaz Notta2. 1University of Toronto, Toronto, ON, Canada, 2University Health Network, Toronto, ON, Canada, 3Ontario Institute of Cancer Research, Toronto, ON, Canada.

**PO-079**  
Proteomic profiling reveals subtype specific kinase expression in pancreatic cancer. Yi Xu, Michael East, Ashley Morrison, Gabriela Herrera, Laura Peng, Gary Johnson, Jen Jen Yeh. UNC Chapel Hill, Chapel Hill, NC.

**PO-080**  
Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD.

Signaling

PO-081  Studying MYC’s contribution to replication stress at the nuclear pore. Gabriel M. Cohn, Colin J. Daniel, Daniel F. Liefwalker, Rosalie C. Sears. Oregon Health & Science University, Portland, OR.

PO-082  Delineating the molecular basis of early dissemination of pancreatic cancer. Taelor Ekstrom¹, Dmytro Grygoryev¹, Terry Morgan², Kenneth S Zaret³, Jungsun Kim⁴. ¹Cancer Early Detection Advanced Research Center, Oregon Health & Science University, Portland, OR, ²Cancer Early Detection Advanced Research Center, Department of Pathology, Knight Cancer Institute (Cancer Biology Research Program), Oregon Health & Science University School of Medicine, Portland, OR, ³Institute for Regenerative Medicine, Department of Cell and Developmental Biology, Abramson Cancer Center (Tumor Biology Program), University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁴Cancer Early Detection Advanced Research Center, Department of Molecular and Medical Genetics, Knight Cancer Institute (Cancer Biology Research Program), Oregon Health & Science University School of Medicine, Portland, OR.

PO-084  The role of p53 in the development of pancreatic ductal adenocarcinoma. Kathryn J. Hanson, Brittany M. Flowers, Nicholas Hughes, Hannes Vogel, Le Cong, Laura D. Attardi. Stanford University, Stanford, CA.


PO-088  Classification based on efficiency of mRNA translation reveals a metabolically-dependent subtype of pancreatic cancer. Sauyeun Shin¹, Remy Nicolle², Mehdi Liauzun¹, Jacobo Solorzano¹, Alexia Brunel¹, Christine Jean¹, Remi Samain¹, Jerôme Raffenne¹, Cindy Neuzillet³, Carine Joffre⁴, Stephane Roccì⁵, Juan Iovanna⁶, Nelson Dusetti⁶, Ola Larsson⁷, Stephane Pyronnet¹, Corinne Bousquet¹, Yvan Martineau¹. ¹CRCT, Inserm U1037, Toulouse, France, ²CIT, Ligue Nationale Contre Le Cancer, Paris, France, ³Medical Oncology Department, Curie Institute, Saint Cloud, France, ⁴CRCT Inserm U1037, Toulouse, France, ⁵C3M, Inserm U1065, Nice, France, ⁶CRCM, Inserm, Marseille, France, ⁷Karolinska Institutet, Stockholm, Sweden.

PO-089  Identification of a LAMC2-regulated network featuring targetable effectors for dual therapies in pancreatic cancer. Shruthi Narayanan¹, Oihane Erice², Iker Feliu², Caterina Vicentini³, Rodrigo Entrialgo-Cadierno³, Karmele Valencia², Elisabet Guruceaga⁴, Purvesh Khatri⁵, Vicenzo Corbo³, Silvestre Vicent Cambra⁶, Mariano Ponz-Sarvise¹. ¹Clinica Universidad de Navarra, Medical Oncology Department, Pamplona, Spain, ²University of Navarra, Center for Applied Medical Research, Program in Solid Tumors, Pamplona, Spain, ³Department of Diagnostics and Public Health, University of Verona, Verona, Italy, ⁴University
of Navarra, Center for Applied Medical Research, Pamplona, Spain, 5Stanford University, Stanford, CA, 6University of Navarra, Center for Applied Medical Research, Program in Solid Tumors and Department of Pathology, Anatomy and Physiology; IdiSNA, Navarra Institute for Health Research; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain, Pamplona, Spain.

PO-090 TGF-β induced EMT gene expression is associated with promoter demethylation in pancreatic cancer. Manjul Rana1, Abul Elahi1, Abidemi O. Ajidahun1, Rita G. Kansal1, Anders E. Berglund2, David Shibata1, Evan S. Glazer1. 1UTHSC, Memphis, TN, 2Moffitt Cancer Center, Tampa, FL.

PO-091 Histamine receptor 1 (HRH1): A potentially novel G protein-coupled receptor (GPCR) therapeutic target in pancreatic adenocarcinoma (PDAC) cells and tumors. Cristina Salmeron, Krishna Sriram, Mehrak Javadi-Paydar, Paul A. Insel. 1UCSD, La Jolla, CA.

PO-092 Influence of the IL-13-receptor alpha 1 chain on the malignant phenotype of pancreatic cancer cells. Jingwei Shi, Marko Kornmann, Benno Traub. University of Ulm, Ulm, Germany.

PO-093 JNK2 suppresses the growth and invasion of pancreatic cancer and is opposed by JNK1. Jingwei Shi, Xiaodong Tian, Marko Kornmann, Benno Traub. University of Ulm, Ulm, Germany.

PO-094 Gα13 loss in KPC mouse model promotes well-differentiated pancreatic tumors that are susceptible to mTOR inhibition. Mario A. Shields, Christina Spaulding, Mahmoud G. Khalafalla, Thao N. D. Pham, Hidayatullah G. Munshi. Northwestern University, Chicago, IL.

Tumor Microenvironment

PO-095 A cancer cell-intrinsic GOT2-PPARδ axis suppresses antitumor immunity. Jaime Abrego1, Hannah Sanford-Crane1, Chet Oon1, Xu Xiao2, Courtney Betts1, Duanchen Sun3, Shanthi Nagarajan4, Zheng Xia3, Lisa Coussens1, Peter Tontonoz5, Mara Sherman1. 1Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, OR, 2Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, 3Computational Biology Program, Oregon Health & Science University, Portland, OR, 4Medicinal Chemistry Core, Oregon Health & Science University, Portland, OR, 5Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.

PO-096 The synaptic protein Netrin G1 ligand (NGL-1) modulates tumorigenesis and immunosuppression in pancreatic cancer. Debora Barbosa Vendramini Costa1, Ralph Francescone1, Janusz Franco-Barraza1, Tiffany Luong1, Nina Steele2, Benjamin Allen2, Marina Pasca di Magliano3, Charline Ogier1, Igor Astsaturov1, Kathy Q Cai1, Andres J Klein-Szanto1.
Huamin Wang, Kerry Campbell, Edna Cukierman. Fox Chase Cancer Center, Philadelphia, PA, Department of Cell and Developmental Biology, University of Michigan, Ann Arbor, MI, Department of Surgery, University of Michigan, Ann Arbor, MI, Department of Anatomical Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.

PO-097 Addition of losartan to FOLFIRINOX and chemoradiation reduces the expression of pro-invasive and immunosuppressive genes in locally-advanced pancreatic cancer. Yves Boucher, Jessica M. Posada, Sohu Subudhi, Ashwin S. Kumar, Ivy X. Chen, Mei R. Ng, Mari Mino-Kenudson, Nilesh Talele, Dan G. Duda, Dai Fukumura, Janet E. Murphy, Jeffrey W. Clark, David P. Ryan, Carlos Fernandez-Del Castillo, Theodore S. Hong, Rakesh K. Jain. Massachusetts General Hospital and Harvard Medical School, Boston, MA, Massachusetts General Hospital, Boston, MA, Massachusetts General Hospital, Harvard Medical School, Boston, MA.


PO-100 Lorazepam promotes desmoplasia and ischemic necrosis in murine pancreatic ductal adenocarcinoma. Abigail C. Cornwell, Abdulrahman A. Alahmari, Arwen A. Tisdale, Kathryn Maraszek, Swati Venkat, Michael E. Feigin. Roswell Park Comprehensive Cancer Center, Buffalo, NY.


PO-102 Fibroblast-derived interleukin-33 promotes pancreatic ductal adenocarcinoma as a result of tumor cell KRASG12D. Katelyn Donahue, Wenting Du, Carlos Espinoza, Eileen Carpenter, Kristee Brown, Nina Steele, Marina Pasca di Magliano. University of Michigan, Ann Arbor, MI.

PO-103 Cellular origin influences immune microenvironment in a pancreatic cancer mouse model with loss of Pten and activation of Kras. Yan Dou, Wesley Hunt, Justin Chhuor, Farnaz Taghizadeh, Atefeh Samani, Karnjit Sarai, Claire Dubois, David F. Schaeffer, Maike Sander, Janel L. Kopp. University of British Columbia, Vancouver, BC, Canada, University of California-San Diego, La Jolla, CA.
PO-104  Activation of WNT signaling in CD4+ T cells promotes immune suppression in pancreatic cancer. Wenting Du, Rosa E. Menjivar, Katelyn Donahue, Ashley Velez-Delgado, Marina Pasca di Magliano. University of Michigan, Ann Arbor, MI.

PO-105  Overcoming stromal barriers in PDA with a novel polymeric Toll-like receptor agonist. Christopher C. DuFort1, Ciana L. Lopez2, Martin C. Whittle1, Vladimir Vlaskin3, Aditi Vadodkar4, Selvi Srinivasan2, Patrick S. Stayton2, Sunil R. Hingorani1. 1Fred Hutchinson Cancer Research Center, Seattle, WA, 2University of Washington, Seattle, WA.

PO-106  The extrinsic and modulatory effects of CSF-1/CSF-1R signaling in generating an immunosuppressive pancreatic cancer tumor microenvironment and promoting metastasis. Gizem Efe1, Kensuke Suzuki1, Jason R. Pitarresi2, Anna M. Chiarella1, Alina L. Li1, Anil K. Rustgi1. 1Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, 2Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.

PO-107  Fibroblast differentiation trajectories elicit regional tissue states in pancreatic cancer Barbara T. Grünwald1, Curtis McCluskey1, Antoine Devisme2, Foram Vyas1, Geoffroy Andrieux2, Kazeera Aliar1, Faiyaz Notta3, Grainne O’Kane1, Julie Wilson3, Jennifer Knox1, Sandra Fischer4, Thomas Kislinger1, Melanie Boerries2, Steven Gallinger3, Rama Khokha5. 1Princess Margaret Cancer Centre, Toronto, ON, Canada, 2University of Freiburg, Freiburg, Germany, 3Ontario Institute for Cancer Research, Toronto, ON, Canada, 4University Health Network, Toronto, ON, Canada, 5Princess Margaret Cancer Centre, Toronto, Canada.

PO-108  Evaluation of antitumor activity of modified-gemcitabine solid-lipid nanoparticle in pancreatic pdx models. Edward Agyare1, Taylor Smith2, Andriana Inkoom1, Bo Han3, Jose Trevino4, Nkafu Bechem Ndemazie1. 1College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL, 2Food and Drug Administration, Silver Spring, MD, 3Keck School of Medicine, University of Southern California, Los Angeles, CA, 4Department of Surgery, College of Medicine, Virginia Commonwealth University, Richmond, VA.

PO-110  Targeting Cathepsin B in the pancreatic stellate cells stimulates CD8+ T cell dependent anti-tumor immune response. Bharti Garg, Tejeshwar Jain, Utpreksha Vaish, Vikas Dudeja. University of Alabama at Birmingham, birmingham, AL.

PO-111  A Human Single-cell RNA Sequencing Atlas of Pancreatic Ductal Adenocarcinoma Enables Harmonized Cell Type Calling and Comprehensive Analyses of Potential Intercellular Signaling. Benedict Kinny-Köster1, Melissa R. Lyman2, Dimitrios N. Sidiropoulos2, Melanie Loth2, Alexandra B. Puscek2, Laura D. Wood3, Jin He1, Jun Yu1, Richard A. Burkhart1, Elizabeth M. Jaffee2, Jacquelyn W. Zimmerman2, Elana J. Fertig2. 1Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, 2Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, 3Department of Pathology, Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD.

PO-112  Stromal reprogramming by FAK inhibition overcomes radiation resistance to
allow for immune priming and response to checkpoint blockade. Varintra E. Lander, Jad I. Belle, Brett L. Knolhoff, John M. Herndon, Cedric Mpoy, Buck E. Rogers, Julie K. Schwarz, David G. DeNardo. Washington University in St. Louis, St. Louis, MO.

PO-113 The prolyl isomerase PIN1 plays a critical role in fibroblast differentiation states to support pancreatic cancer. Ellen M. Langer1, Isabel A English1, Vidhi Shah1, Kevin MacPherson1, Kayleigh M. Kresse1, Brittany L. Allen-Petersen2, Colin J. Daniel1, Mara H. Sherman1, Andrew Adey1, Rosalie C. Sears1. 1Oregon Health & Science University, Portland, OR, 2Purdue University, West Lafayette, IN.

PO-114 STAT3 in cancer-associated fibroblasts promotes an immunosuppressive tumor microenvironment. Julia E. Lefler, Michael Ostrowski, Catherine MarElia-Bennett. Medical University of South Carolina (MUSC), Charleston, SC.

PO-115 Effects of mesothelin exert on tumor microenvironment in pancreatic ductal adenocarcinoma. Dongliang Liu1, Ethan Poteet, Zhengdong Liang, Emily Laplante, Lisa Brubaker, Sadhna Dhingra, Aleksandar Milosavljevic, Changyi Chen, Qizhi Cathy Yao. Baylor College of Medicine, Houston, TX.

PO-116 Deletion of Arginase 1 in myeloid cells alters the pancreatic cancer microenvironment. Rosa E. Menjivar1, Zeribe Nwosu1, Wenting Du1, Katelyn Donahue1, Carlos Espinoza1, Ashley Velez-Delgado1, Kristee Brown1, Wei Yan1, Christopher Halbrook2, Yaqing Zhang1, Costas Lyssiotis1, Marina Pasca di Magliano1. 1University of Michigan, Ann Arbor, MI, 2University of California Irvine, Irvine, CA.

PO-117 The role of Hippo signaling in stromal-epithelial interactions in acinar-to-ductal metaplasia and pancreatic cancer initiation. Julia Messina-Pacheco1, Yasser Riazi-Alhosseini2, Zu-hua Gao1, Alex Gregorieff1. 1Department of Pathology, McGill University and the Research Institute of McGill University Health Centre, Montreal, QC, Canada, 2Department of Human Genetics, McGill University and the McGill University and Genome Quebec Innovation Centre, Montreal, QC, Canada.

PO-118 The tumor immune microenvironment is decisive in the survival of pancreatic ductal adenocarcinoma. Hosein M. Aziz, Lawlaw Saida, Willem de Koning, Andrew Stubbs, Yunlei Li, Casper H. J. van Eijck, Dana A. M. Mustafa. Erasmus University Medical Center, Rotterdam, Netherlands.

PO-119 DFMO mediated improvement in survival of an orthotopic model of pancreatic cancer is associated with modulating immune suppression in the tumor microenvironment. Sai Preethi Nakkina1, Sarah B. Gitto2, Veethika Pandey2, Jordan M. Beardsley1, Michael W. Rohr1, Jignesh G. Parikh3, Otto Phanstiel4, Deborah A. Altomare1. 1University of Central Florida, Orlando, FL, 2University of Pennsylvania, Philadelphia, PA, 3Orlando VA Medical Center, Orlando, FL, 4College of Medicine, University of Central Florida, Orlando, FL.

PO-120 Differential expression of polyamine pathways in human pancreatic tumor progression and effects of polyamine blockade therapy on the in vivo pancreatic tumor
**microenvironment.** Sai Preethi Nakkina¹, Sarah B. Gitto², Veethika Pandey², Jignesh G. Parikh³, Dirk Geerts⁴, Kenneth P. Olive⁵, Otto Planstiel⁶, Deborah A. Altmare¹, Carlo Maurer⁷.
¹University of Central Florida, Orlando, FL, ²University of Pennsylvania, Philadelphia, PA, ³Orlando VA Medical Center, Orlando, FL, ⁴University of Amsterdam, Amsterdam, Netherlands, ⁵Columbia University Medical Center, New York, NY, ⁶College of Medicine, Orlando, FL, ⁷Klinikum rechts der Isar der TUM München, Munich, Germany.

PO-121 Investigating the role of human cancer-associated fibroblasts in pancreatic cancer invasion using patient-derived PDAC organoids. Bernat Navarro-Serer, Kenna Sherman, Laura D. Wood. Johns Hopkins University School of Medicine, Baltimore, MD.

PO-122 Combined CDK and BET inhibition reprograms the tumor and stromal compartments to enhance anti-tumor immunity in immunologically-cold CDKN2A-deficient pancreatic cancer. Brian M. Olson, Alison J. Thomas, Michael B. Ware, Gregory B. Lesinski. Emory University, Atlanta, GA.

PO-123 Development of a 3D Biomimetic Metastatic Liver Niche Model for Pancreatic Cancer. Mahsa Pahlavan¹, Weikun Xiao², Flora Eun², Chang-II Hwang³, Reginald Hill².
¹Department of Biomedical Engineering, University of Southern California, Los Angeles, CA, ²Lawrence J. Ellison Institute for Transformative Medicine of USC, University of Southern California, Los Angeles, CA, ³Department of Microbiology and Molecular Genetics, College of Biological Sciences, University of California Davis, Davis, CA.

PO-124 EZH2 blockade overcomes suppression of the proinflammatory senescence-associated secretory phenotype in the pancreas and drives NK cell-mediated pancreatic tumor responses. Loretah Chibaya¹, Yvette Lopez-Diaz¹, Haibo Liu¹, Katherine C Murphy¹, John P. Morris IV², Yu-jui Ho², Janelle Simon², Wei Luan², Amanda Kulick², Lakhena Leang¹, Elisa de Stanchina², Lihua J. Zhu¹, Scott W. Lowe², Marcus Ruscetti¹.
¹University of Massachusetts Medical School, Worcester, MA, ²Memorial Sloan Kettering Cancer Center, New York, NY.

PO-125 The role of KDM6A in pancreatic cancer immune microenvironment. Lin Jin, Jing Yang, Zhujun Yi, Hong S Kim, Feng Tian, Jiaqi Shi. University of Michigan, Ann Arbor, MI.

PO-126 Loss of HIF1A decreases resistance to radiation and invasiveness in pancreatic ductal adenocarcinoma. Kevin J. Tu¹, Sanjit K. Roy¹, Binny Bhandary², Amit Sawant¹, Hem D. Shukla¹.
¹University of Maryland School of Medicine, Baltimore, MD, ²University of Maryland, Baltimore, Baltimore, MD.

PO-127 A uPA/uPAR axis in both the tumor cell and stromal compartment drives PDAC disease progression. Yi Yang, Sara R. Abrams, Aditi Kothari, Harshi Matada, Keely Davey, Alisa S. Wolberg, Matthew J. Flick. University of North Carolina, Chapel Hill, Chapel Hill, NC.

PO-130  Macropinocytosis at the nexus of crosstalk in the pancreatic tumor microenvironment. Yijuan Zhang¹, M. Victoria Recouvreux¹, Michael Jung¹, Koen Galencamp¹, Yunbo Li², Olga Zagnitko¹, David Scott¹, Andrew Lowy², Cosimo Comisso¹. ¹Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, ²University of California San Diego, La Jolla, CA.

PO-131  The role of liver endothelium on pancreatic cancer growth. Wei Zhang¹, Michel’le Wright¹, Moeez Rathore¹, Ali Vaziri-Gohar¹, Jordan Winter², Rui Wang². ¹Case Western Reserve University, Cleveland, OH, ²Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH.